Importantly, palbociclib, a small‐molecule inhibitor of CDK4 and CDK6, combined with letrozole has recently been approved to treat postmenopausal women with ER‐positive, HER2‐negative advanced breast cancer as a first‐line therapy 35. The gene discussed is CDK4; the disease is breast carcinoma.